Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31627938 | 0.85 | UCHL1 (0.37) | GPR119KDM1AUCHL1DDB1CRBN | |
| SCHEMBL33532844 | 0.81 | UCHL1 (0.44) | GPR119UCHL1DDB1CRBNHTR2C | |
| SCHEMBL30878573 | 0.81 | UCHL1 (0.39) | UCHL1DDB1CRBNHTR2CHTR2B | |
| SCHEMBL30878549 | 0.81 | GPR119 (0.47) | GPR119KDM1APDE4B | |
| SCHEMBL33532841 | 0.80 | UCHL1 (0.38) | UCHL1DDB1CRBNNR1I2 | |
| SCHEMBL24495434 | 0.78 | UCHL1 (0.43) | UCHL1DDB1CRBN | |
| SCHEMBL30682966 | 0.78 | UCHL1 (0.43) | UCHL1DDB1CRBN | |
| SCHEMBL7996670 | 0.77 | UCHL1 (0.43) | GPR119KDM1AUCHL1DDB1CRBN | |
| SCHEMBL17681742 | 0.77 | UCHL1 (0.55) | GPR119UCHL1DDB1CRBNNR1I2 | |
| SCHEMBL17681690 | 0.77 | UCHL1 (0.55) | GPR119UCHL1DDB1CRBNNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | GPR119 3701/4885KDM1A 4208/4885UCHL1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.